Alkermes Archives -

The FDA approval of Alkermes’ new antipsychotic drug Lybalvi couldn’t have gone any better for the company, but

After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi

https://pharmaphorum.com/news/after-fda-approval-alkermes-plans-soft-launch-for-antipsychotic-lybalvi/

Alkermes has agreed a $950 million deal to acquire Rodin Therapeutics, a US biotech developing drugs for neurodegenerative

Alkermes bolts on Rodin Therapeutics to bulk up thin pipeline

https://pharmaphorum.com/news/alkermes-bolts-on-rodin-therapeutics-to-bulk-up-thin-pipeline/

Alkermes is facing a significant delay for its ALKS 5461 candidate for major depressive disorder after the FDA

Alkermes rebuffed by FDA on antidepressant

https://pharmaphorum.com/news/alkermes-rebuffed-by-fda-on-antidepressant/

Alkermes and Biogen have filed a new multiple sclerosis pill with the FDA, which they hope will treat

Alkermes/Biogen hope for less tummy trouble with new MS pill

https://pharmaphorum.com/news/alkermes-biogen-hope-for-less-tummy-trouble-with-new-ms-pill/

Alkermes is planning to head to the FDA next year with a new schizophrenia drug that, according to

Alkermes preps filing for weight-friendly schizophrenia drug

https://pharmaphorum.com/news/alkermes-preps-filing-for-weight-friendly-schizophrenia-drug/

Sage’s Zulresso (brexanolone) is on course for approval for postnatal depression in the US after a positive vote

FDA panel backs Sage’s novel antidepressant but turns down Alkermes’

https://pharmaphorum.com/news/fda-panel-backs-sages-novel-antidepressant-but-turns-down-alkermes/

ALKS 8700 may have fewer side effects than Tecfidera.

Alkermes closing in on Biogen with MS rival

https://pharmaphorum.com/news/alkermes-closing-biogen-ms-challenger/

Alkermes